> All News
> BASL News
> Hepatology News
> Nurse News
> Trainee News
> Transplant News
News Articles 91 - 100 of 160
BASL is offering two competitive awards in 2018 up to a value of £3,000 each to contribute to the costs of an international attachment in clinical liver disease (including liver transplantation and liver surgery) or research into any aspect of liver disease.
Applications are open to any healthcare professional or scientist working in the field of liver disease who are members of BASL, BLNA, BLTG or BASL affiliated groups.
To find out further details and how to apply download the information document here; Download BASL professional development awards final 15.3.18.pdf
The deadline for submitting your application is 17:00 on Friday 29th June 2018.
Applications should be emailed to the BASL Secretariat at email@example.com .
The 100,000 genomes project will finish recruiting around September of this year.
There is a category for liver - ‘ductal plate malformation’ - which enables patients to be entered with any form of congenital liver disease including vascular.
Please liaise with your local clinical genetics department regarding any outstanding cases so that we can maximise numbers nationally.
Consultant Hepatologist, Cambridge
Job Reference: 321-SS-HEP-ALN-B7
Employer: Oxford University Hospitals NHS Foundation Trust
Location: John Radcliffe Hospital, Oxford
Salary: £31,696 - £41,787 per annum
Closing Date: 13 May 2018
Full details can be found on the NHS Jobs site > here.
Health, homelessness and children’s leaders have urged the government to implement minimum unit pricing (MUP) for alcohol in England.
The calls come as MUP comes into effect in Scotland, where it is expected to reduce alcohol deaths and levels of alcohol-related harm, as well as cut crime and reduce costs to the health service.
Campaigners said that, following the roll out of MUP in Scotland, it is vital that England does not get left behind in terms of reducing the harm done by alcohol. Campaigners pointed to estimates which suggest that, if MUP in England were to be delayed by 5 years, over a thousand lives could be lost.
MUP works by setting a floor price below which a unit of alcohol cannot be sold. In Scotland, this floor price will be set at 50p per unit. This means that a pint of beer containing 2 units will now have to cost at least £1, and a bottle of wine containing 9 units will have to cost at least £4.50.
The measure is designed to increase the price of the cheapest, strongest drinks consumed by those experiencing the worst alcohol-related harms.
In practice, MUP will leave prices in pubs, bars and restaurants virtually untouched, and raise the price of products like supermarket own-brand vodka and super-strength lagers, which are typically consumed by the most vulnerable groups, such as children and street drinkers.
Moderate drinkers are estimated on average to barely change their consumption or spending in response to MUP.
In response to the introduction of MUP in Scotland, and commenting on the need for the measure in England, Professor Sir Ian Gilmore, chair of the Alcohol Health Alliance UK (AHA), said:
‘We congratulate the Scottish government on the introduction of minimum unit pricing. The Westminster government should now follow Scotland’s lead, and introduce MUP in England.
‘Cheap alcohol is wrecking lives and livelihoods in England as well as Scotland. There are more than 23,000 deaths a year in England due linked to alcohol, and many of these come from the poorest and most vulnerable sections of society.
‘Minimum unit pricing will save lives, cut crime and benefit the public finances. At the same time, pub prices will be left untouched, and moderate drinkers will barely notice the difference under MUP.
‘Any delay in implementing MUP in England will only cost lives and lead to unnecessary alcohol-related harm. We urge the Westminster government to act now.’
About the Alcohol Health Alliance UK
The Alcohol Health Alliance UK (AHA) is a group of over 50 organisations and works together to:
- Highlight the rising levels of alcohol-related health harm
- Propose evidence-based solutions to reduce this harm
- Influence decision makers to take positive action to address the damage caused by alcohol misuse
For further information, please contact Matt Chorley, the AHA’s Policy and Communications Officer, at firstname.lastname@example.org or on 0203 075 1726.
There is increasing recognition that although great strides have been made in treating liver disease, sadly many patients still succumb to it and need good quality health care in the final stages of their lives, which is sometimes lacking compared to other diseases.
In the discussion document below, which came out of two recent meetings by the BASL End of Life Care Special Interest Group, we outline the key issues and suggest a plan of action going forward to improve matters.
Contributors: Mark Wright, Michael Allison, Ben Hudson, Suzanne Ford-Dunn, Fiona Finlay, Graeme Alexander and the BASL End of Life Care Special Interest Group.
Over the last few years there has been increasing discussion about the role of early liver transplantation for patients with severe alcoholic hepatitis not responding to medical treatment. Although this is increasingly being considered in France and the US, uptake of a pilot study of liver transplantation for this condition in the UK over the last few years was extremely low. We are interested therefore to understand where UK clinicians who look after patients with severe alcoholic hepatitis see the role of early liver transplantation in this setting and would therefore be very grateful if you would be able to complete this Survey, which has been BASL endorsed, and should take only 2-3 minutes to complete.
Please find to follow the link to the survey - www.centralnhs.com .
Many thanks for your help
Katie Arndtz, Gastroenterology SpR
Alexander Gimson, Consultant Hepatologist
Michael Allison, Consultant Hepatologist
The 2018 Gilead UK and Ireland Fellowship Programme is now open for grant applications in viral hepatitis.
The aim of the Programme is to support local innovation and best practice in patient care in HIV, viral hepatitis, oncology/haematology, respiratory and invasive fungal disease.
The Programme invites applications from healthcare or allied professionals who are seeking funding for a project that aligns with the goals of the Gilead UK & Ireland Fellowship Programme.
The 2018 Viral Hepatitis Fellowship programme will support projects aligned to the theme:
Systematic HCV testing (or re-engagement of those previously diagnosed) in at-risk populations in community-based services (e.g. community pharmacy, correctional services, etc) including community-based treatment initiation.
To view the application criteria and apply visit: www.gileadgiving.co.uk , all applications must be made via the online form.
Please note that the application period will close on Friday 1 June 2018
For specific application queries, please contact the Gilead UK and Ireland Fellowship Administrators on: email@example.com .
Public Health England (PHE) has recently published a recovery plan on gov.uk to support re-introduction of hepatitis B vaccine in a phased approach during 2018 for lower priority groups mainly vaccinated by occ health and primary care.
View a letter from PHE here: Download PHE letter to stakeholders _hepB vaccine recovery plan 2018.pdf
The link to the recovery plan on the gov.uk website can be found > here.
Welcome to the Europe and Canada Practice to Policy® Health Awards Programme
In 2018, Intercept is excited to offer grant support to local and national projects within eligible countries across Europe and Canada. The Europe and Canada Practice to Policy® Health Awards Programme encourages the development of innovative projects which improve the lives of people with primary biliary cholangitis (PBC).
The application window is now open.
Please note that the deadline for applying is Wednesday 6 June 2018.
Visit the website here - https://www.interceptpracticetopolicy.com/eu .
Job Reference: 304-18C011
Employer: University Hospitals Birmingham NHS Foundation Trust - Medical & Dental
Location: Birmingham, Queen Elizabeth Hospital
Salary: £76,761 - £103.490
Closing Date: 31 March 2018
Applications are invited for 2 x 1.0 WTE Hepatology Consultants (10 PAs) to join the existing liver medicine team. The successful applicants will work as Transplant Physicians within the Department of Hepatology. The department consists of 14 Consultant Hepatologists (including 6 Transplant Physicians and 6 Academic Hepatologists), 3 Hepatology Fellows and 8 specialist hepatology trainees. The successful applicant will contribute to clinical service development and delivery as a member of the hepatology team, working closely with colleagues in the Liver and Hepatobiliary Unit, Interventional Radiology and Oncology.
Full details can be found on the NHS Jobs site > here.